NewAmsterdam Pharma (NASDAQ:NAMS) CAO Sells 39,816 Shares

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) CAO Louise Frederika Kooij sold 39,816 shares of the firm’s stock in a transaction dated Tuesday, January 27th. The shares were sold at an average price of $32.62, for a total value of $1,298,797.92. Following the transaction, the chief accounting officer directly owned 24,353 shares in the company, valued at approximately $794,394.86. This represents a 62.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website.

Louise Frederika Kooij also recently made the following trade(s):

• On Wednesday, January 28th, Louise Frederika Kooij sold 32,612 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $31.80, for a total value of $1,037,061.60.
• On Monday, January 26th, Louise Frederika Kooij sold 34,400 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $32.78, for a total value of $1,127,632.00.
• On Friday, January 23rd, Louise Frederika Kooij sold 38,172 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.75, for a total value of $1,288,305.00.
• On Monday, January 5th, Louise Frederika Kooij sold 2,647 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $33.25, for a total transaction of $88,012.75.
• On Friday, December 26th, Louise Frederika Kooij sold 43,872 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $35.30, for a total value of $1,548,681.60.
• On Tuesday, December 23rd, Louise Frederika Kooij sold 75,117 shares of NewAmsterdam Pharma stock. The stock was sold at an average price of $36.21, for a total value of $2,719,986.57.
• On Wednesday, December 24th, Louise Frederika Kooij sold 26,011 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $35.68, for a total value of $928,072.48.

NewAmsterdam Pharma Stock Down 1.4%

Shares of NASDAQ:NAMS traded down $0.44 during trading on Thursday, hitting $31.44. The stock had a trading volume of 329,968 shares, compared to its average volume of 715,688. The company has a market capitalization of $3.57 billion, a PE ratio of -15.34 and a beta of 0.07. The firm’s fifty day moving average is $35.32 and its 200 day moving average is $31.25. NewAmsterdam Pharma Company N.V. has a 12 month low of $14.06 and a 12 month high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last posted its earnings results on Wednesday, November 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.38) by ($0.03). NewAmsterdam Pharma had a negative net margin of 627.59% and a negative return on equity of 28.30%. The company had revenue of $0.35 million for the quarter, compared to the consensus estimate of $4.54 million. Equities research analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Investors Weigh In On NewAmsterdam Pharma

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. raised its stake in NewAmsterdam Pharma by 3.0% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 16,607,074 shares of the company’s stock valued at $300,754,000 after purchasing an additional 490,656 shares during the period. Capital World Investors increased its stake in NewAmsterdam Pharma by 17.1% in the 3rd quarter. Capital World Investors now owns 9,822,711 shares of the company’s stock worth $279,358,000 after buying an additional 1,434,986 shares during the period. Jennison Associates LLC increased its holdings in NewAmsterdam Pharma by 42.5% during the 3rd quarter. Jennison Associates LLC now owns 4,198,554 shares of the company’s stock worth $119,407,000 after purchasing an additional 1,252,451 shares during the period. Wellington Management Group LLP grew its holdings in NewAmsterdam Pharma by 21.0% during the 3rd quarter. Wellington Management Group LLP now owns 4,020,126 shares of the company’s stock worth $114,332,000 after acquiring an additional 697,129 shares in the last quarter. Finally, Adage Capital Partners GP L.L.C. boosted its position in NewAmsterdam Pharma by 54.5% during the 2nd quarter. Adage Capital Partners GP L.L.C. now owns 3,013,009 shares of the company’s stock valued at $54,566,000 after acquiring an additional 1,062,359 shares in the last quarter. Institutional investors own 89.89% of the company’s stock.

Wall Street Analyst Weigh In

NAMS has been the topic of several research reports. Stifel Nicolaus raised their target price on NewAmsterdam Pharma from $44.00 to $50.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Leerink Partners reissued an “outperform” rating and issued a $55.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, January 6th. Weiss Ratings restated a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research report on Thursday, January 22nd. Royal Bank Of Canada increased their price target on shares of NewAmsterdam Pharma from $44.00 to $47.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 21st. Finally, The Goldman Sachs Group lifted their price target on shares of NewAmsterdam Pharma from $30.00 to $37.00 and gave the stock a “neutral” rating in a research note on Tuesday, December 2nd. Nine equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $47.00.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.